The prevalence and prognostic value of KRAS co ‐mutation subtypes in Chinese advanced non‐small cell lung cancer patients
ConclusionOur study revealed that concurrent genomic alterations can further stratify KRAS ‐mutant lung adenocarcinoma patients into various subgroups with distinctive therapeutic responses and differential survival outcomes. The KPL is a novel and less responsive subtype amongKRAS‐mutated NSCLC, and further investigation of effective treatment for this subtype is warranted.
This study is aimed at reviewing the signaling pathways that underlie ginsenosides-triggered apoptotic process and encourage further studies to target promising agents against lung cancer treatment. PMID: 31795742 [PubMed - as supplied by publisher]
ConclusionsThe uptake of [18F]FAMT on PET imaging was significantly correlated with PD-L1 expression in NSCLC, especially in patients with AC and advanced disease.
Conclusions: EGFR mutated in 10%, mostly in women and non-smokers, all of them adenocarcinoma. Low prevalence of the other mutations. Mutation of EGFR has better prognosis. In the multivariate analysis, the IVA vs IVB stage, ECOG, RT and treatment with ITK in mutated EGFR leads to a better prognosis.
Conclusion: Bronchoscopic re-biopsy for progressive lung cancer is feasible and safe. Histological change can be detected in a considerable number of patients, which is potentially valuable information for guidance of subsequent treatment.
Background: Atezolizumab (anti-PD-L1 antibody) can be used with anti-PD-1 antibodies (nivolumab and pembrolizumab) for treating NSCLC. The safety and efficacy of atezolizumab are unclear in patients who were previously treated with anti-PD-1 antibodies.Aim: To investigate the efficacy and safety of atezolizumab in patients who previously received anti-PD-1 antibodies.Methods: We retrospectively reviewed NSCLC patients who received atezolizumab after receiving anti-PD-1 antibodies. We evaluated tumour PD-L1 expression, cycles of anti-PD-1/PD-L1 antibodies, best response, progression free survival, and prior chemotherapies.R...
Conclusions: In experienced hands, pneumonectomy should be offered to patients despite risk of N2 disease provided N2 involvement is limited to unisite or skip N2 disease. Multimodality treatment including surgery should be offered to provide a fair overall and disease free survival.
Conclusions: IPF is a risk factor for lung cancer development. Squamous cell carcinoma is the most common histologic subtype in patients with IPF. Large randomized controlled studies on the management of patients with IPF and lung cancer are sorely needed.
SUMMARY AIM To examine the relationship between treatment response and hypoxia-inducible factor-1 alpha (HIF-1 α ) levels in patients with locally advanced non-small cell lung cancer (NSCLC) who received chemoradiotherapy (CRT). METHODS Eighty patients with NSCLC were included in the study and treated at Acibadem Mehmet Ali Ayd ı nlar University Medical Faculty. HIF-1 α levels were measured before and after CRT by the enzyme-linked immunosorbent assay (ELISA) method. RESULTS Patients ’ stages were as follows; stage IIIA (65%) and stage IIIB (35%). Squamous histology was 45%, adenocarcinoma was 44%, and o...
Expression of DR5 and c‑FLIP proteins as novel prognostic biomarkers for non‑small cell lung cancer patients treated with surgical resection and chemotherapy. Oncol Rep. 2019 Oct 04;: Authors: Zheng H, Zhang Y, Zhan Y, Liu S, Lu J, Wen Q, Fan S Abstract TRAIL‑R2 (DR5), one of the death receptors, can activate the extrinsic apoptosis pathway, while cellular FLICE‑inhibitory protein (c‑FLIP) can inhibit this pathway. Both of them play important roles in the occurrence and development of most tumors. To date, there is no relevant report concerning the relationship between expression of DR5 and c...
ConclusionA very difficult case of grade V immune-related thrombocytopenia after the administration of nivolumab as second-line therapy for relapsed lung adenocarcinoma was described. Immune-related thrombocytopenia is a rare adverse event, but it must be considered a possible complication because it may become critical once it has occurred.